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One hundred clinical isolates of Cryptococcus neoformans from human immunodeficiency virus (HIV)-
infected and non-HIV-infected patients from Brazil, Chile, and Venezuela were separated according to varieties
and tested for antifungal susceptibility. A high susceptibility to antifungal agents was observed among all the
isolates. The electrophoretic karyotyping of 51 strains revealed good discrimination among Cryptococcus
neoformans var. neoformans strains.
An increase in the incidence of cryptococcosis has been
reported in recent years and is associated with the growing
population of immunocompromised patients and the human
immunodeficiency virus (HIV) epidemic. In Brazil, 4.5% of all
opportunistic infections in AIDS patients have been reported
as being caused by Cryptococcus neoformans (6). Distribution
of serotypes and varieties is considered to be regionally spe-
cific, but Cryptococcus neoformans var. neoformans serotype A
has been recovered from approximately 99% of all AIDS pa-
tients in most countries (7). The evaluation of antifungal sus-
ceptibility of C. neoformans is of great interest, considering the
high frequency and the severe clinical manifestations of this
infection (1). DNA typing methods have shown a high genetic
heterogeneity among clinical and environmental isolates of C.
neoformans (3, 9). Most studies in Latin America have been
limited to clinical and epidemiological aspects (10, 11), and
only few investigations have studied the molecular epidemiol-
ogy of clinical isolates from this area (3). Therefore, we studied
clinical isolates of C. neoformans isolates from three countries
in South America according to their varieties, serotypes, anti-
fungal susceptibilities, and genomic diversity, as determined by
electrophoretic karyotype (EK).
One hundred clinical isolates C. neoformans from Brazil (69
isolates), Venezuela (20 isolates), and Chile (11 isolates) were
investigated. Sixty strains were obtained from HIV-positive
patients, 16 were obtained from HIV-negative patients, and for
24 patients, the data on HIV status were not available. The
isolates were identified to species level based on micromor-
phological and biochemical characteristics (5). Canavanine-
glycine-bromthymol blue agar medium was used for the differ-
entiation of the varieties (4), and serotyping was performed by
slide agglutination test (Crypto Check; Iatron Co., Japan). All
the isolates were tested by broth microdilution method, per-
formed according to the NCCLS guidelines (8) for amphoter-
icin B (AMB), fluconazole (FLC), itraconazole (ITC), and
flucytosine (5FC). Broth microdilution testing was performed
with RPMI 1640 with L-glutamine, without bicarbonate, and
buffered with MOPS (morpholinepropanesulfonic acid) at pH
7.0. Candida parapsilosis ATCC 22019 was included on each
test as quality control strain. Breakpoints for azole and 5FC
MICs were defined as the lowest drug concentration resulting
in a prominent decrease in turbidity, compared with that in the
growth control (drug-free) well. The AMB MICs were defined
as the lowest concentration able to inhibit any visual growth.
Karyotype analysis was done by counter-clamped homoge-
neous electrophoresis (CHEF DRII). The chromosomal DNA
extractions were prepared according to previous protocols (3).
Pulsed-field gel electrophoresis was carried out at 6 V/cm at
13.5°C with pulses of 60 to 120 s for 27 h. A Saccharomyces
cerevisiae chromosomal DNA size standard was inserted in
each gel as a molecular weight standard. Isolates were consid-
ered different if any readily detectable band did not match. A
computer analysis program (Vilber Loumart, Marnes la Valle,
France) was used to determine a dendrogram based on the
Dice coefficient of similarity (5%).
Eighty-nine isolates were identified as C. neoformans var.
neoformans, and 11 were identified as Cryptococcus neoformans
var. gattii. All C. neoformans var. gattii strains were from HIV-
negative patients. Serotyping of 62 isolates of C. neoformans
var. neoformans identified 60 (96.8%) strains as serotype A.
Among the 11 C. neoformans var. gattii strains, nine isolates
were serotype B. No particular serotype distribution was re-
lated to any geographic areas, although three isolates, serotype
AD, were found only among the Chilean isolates. Our data
were consistent with several reports in the literature that re-
ferred to C. neoformans var. neoformans serotype A as pre-
dominant worldwide, especially in AIDS patients (7, 12). How-
* Corresponding author. Mailing address: Infectious Diseases Divi-
sion, Faculdade de Cieˆncias Me´dicas, Universidade Estadual de
Campinas (UNICAMP), Cidade Universita´ria Zeferino Vaz, 13083-
970, Campinas, Sa˜o Paulo, Brazil. Phone: 55-19-3788-7734. Fax: 55-
19-3236-2092. E-mail: moretti@hc.unicamp.br.
2348
ever, detailed surveys are needed to ascertain the prevalence of
serotypes in Latin America countries.
All C. neoformans isolates were susceptible to AMB; 99% of
C. neoformans var. neoformans and 73% of C. neoformans var.
gattii isolates were susceptible to FLC. For 5FC, 90% of the
isolates were susceptible, 9% were intermediate, and one
strain, from Venezuela, was resistant. MIC ranges for C. neo-
formans var. neoformans were as follows, respectively: AMB,
0.125 and 0.5 mg/ml; FLC; 4 and 8 mg/ml; ITC, 0.06 and 0.125
mg/ml; 5FC, 4 and 4 mg/ml. MIC ranges for C. neoformans var.
gattii were as follows: AMB, 0.25 and 0.5 mg/ml; FLC, 8 and 16
mg/ml; ITC, 0.125 and 0.25 mg/ml; 5FC, 2 and 8 mg/ml. The
susceptibility profiles of C. neoformans isolates obtained from
HIV-infected and non-HIV-infected patients, as well as those
of the isolates from different countries, were very similar and
consistent with studies in the literature (2; S. Cordoba, M.
Melhem, S. Pukinskas, M. A. Martins, S. Nery, B. Calvo, W.
Vivot, M. Soria, G. Davel, and L. L. Rodero, Abstr. 39th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1508,
1999). Of note, the MIC90s of azoles obtained with C. neofor-
mans var. gattii were higher than the values obtained with C.
neoformans var. neoformans. However, these values repre-
sented only one tube dilution; additional studies are needed
for further conclusions.
EK was performed with 40 C. neoformans var. neoformans
strains (25 from Brazil, 10 from Venezuela, and 5 from Chile)
and 11 C. neoformans var. gattii strains (8 from Brazil and 3
from Venezuela). C. neoformans var. neoformans presented 18
profiles, while only 3 were observed with C. neoformans var.
gattii. Among the 25 Brazilian isolates of C. neoformans var.
neoformans, 9 profiles were identified. The Venezuelan C. neo-
formans var. neoformans strains had six EK profiles repre-
sented by four unique profiles. Two of the predominant pro-
files of the Brazilian collection were also identified among
Venezuelan strains. Interestingly, five distinctive profiles were
observed only in the five Chilean C. neoformans var. neofor-
mans isolates. In a previous study, Franzot et al. (3) also ob-
served a broad diversity among Brazilian isolates. In our study,
among the 11 C. neoformans var. gattii strains, EK identified
three different profiles and all 7 isolates from the Brazilian
collection exhibited the same profile. No association between
EK profiles and HIV disease or serotypes was observed (Fig. 1
and 2). The distances between the two varieties and serotypes
generated by Dice coefficients are shown in Fig. 2. Among the
18 profiles revealed by EK for C. neoformans var. neoformans,
proper profiles were observed in each country that were not
identified in others. Thus, further analysis is necessary to eval-
uate the significance of geographic distribution in the molec-
ular epidemiology of C. neoformans in Latin America.
In conclusion, C. neoformans serotype A appeared to be the
most prevalent agent of cryptococcosis in Latin America. De-
spite minor differences of antifungal susceptibility exhibited by
the two varieties of C. neoformans, most isolates were suscep-
tible to all drugs tested. Our results provide evidence of a
higher diversity of genotypes among C. neoformans var. neo-
formans isolates than among C. neoformans var. gattii isolates.
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